Track topics on Twitter Track topics that are important to you
US-based neuroscience and technology company electroCore has completed its Series B financing that has brought in just more than $70m of capital.
A round of Series B financing brought in more than $70 million for electroCore, which makes the gammaCore therapy device for -More-
The FDA granted electroCore 510(k) clearance for its gammaCore device for use in acute treatment of migraine pain in adults. -More-
NewsThe financing was led by Core Ventures II, an investment group that previously participated in the Company's Series A round.Contributed Author:&n
The tasks of the project are to map the potency and kinetics of the neurologic, autonomic peripheral, inflammatory, and behavioral responses to vagal nerve stimulation (VNS) vs. sham treat...
electroCore LLC, the New Jersey based bioelectric pharma company, is focused on developing non-invasive vagus nerve stimulation therapies (the gammaCore device) for the treatment ...
electroCore LLC, the New Jersey based bioelectric pharma company, is focused on developing non-invasive vagus nerve stimulation therapies for the treatment of multiple conditions ...
We have published hundreds of electroCore news stories on BioPortfolio along with dozens of electroCore Clinical Trials and PubMed Articles about electroCore for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of electroCore Companies in our database. You can also find out about relevant electroCore Drugs and Medications on this site too.